Cervix Lesion, Human Papilloma Virus, Human Papilloma Virus Infection
Conditions
Keywords
HPV
Brief summary
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV. All the patients included in the study will be Randomized (1:1:1).
Detailed description
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV. All the patients included in the study will be Randomized (1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (usual clinical practice -without treatment-). Selection period of 1 month, followed by randomization and 6 months of treatment followed by a period of another 6 months without treatment. Patients will visit the site into a total of 5 visits throughout the study.
Interventions
DEVICEPapilocare vaginal gel
Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
Sponsors
Adknoma Health Research
Procare Health Iberia S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Woman between the ages of 30 and 65 (both included). 2. Able to read and understand the Patient Information Sheet and the Informed Consent form. 3. Accept participation in the study and sign the Informed Consent form. 4. Cytological result of ASC-US or LSIL or AG-US, with matching colposcopic image, maximum 3 months before the screening visit. 5. Positive HPV by PCR performed at the screening visit (or positive available at most 3 months prior to the baseline visit). 6. Is capable, at the discretion of the investigator, of complying with the requirements of the study protocol and without impediments to follow the instructions and evaluations throughout it.
Exclusion criteria
1. Clinically relevant immune system alterations, or any other autoimmune disease or in treatment with immunosuppressants. 2. Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening visit). 3. To had been vaccinated against HPV. 4. Other symptomatic vulvovaginal infections. 5. Surgical cervical excision in the last year or total hysterectomy. 6. Previous history of gynecological cancer. 7. Participation in any other clinical trial at present or in the 4 weeks prior to the inclusion of the study. 8. Any planned surgery that prevents the correct compliance with the protocol. 9. Use of vaginal contraceptives or other vaginal hormonal treatments. 10. Contraindications for Papilocare gel use or known allergies to any of its components. 11. Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspicion of pregnancy or woman who are breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Repairment of the cervico-vaginal mucosa in positive HPV women measured by normal cytology with concordant colposcopy image | 6 months | Evaluate the repairment of the cervico-vaginal mucosa in positive HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image, 6 months after the start of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Repairment of the cervico-vaginal mucosa in positive HPV women measured by normal cytology with concordant colposcopy image | 3 and 12 months | Evaluate the repairment of the cervico-vaginal mucosa in positive HPV women with a cytological result of squamous atypia of undetermined significance (ASC-US) or low-grade squamous lesion (LSIL) or glandular atypia of undetermined significance (AG-US), with concordant colposcopic image at 3 and 12 months after the start of treatment. |
| Reeptielization of the cervico-vaginal mucosa measured by a likert scale. | 3,6 and 12 months | Evaluate the reeptielization of the cervico-vaginal mucosa months after the start of treatment measured by likert scale, using a total of 5 points (1 is severe ectopy + external bleeding, 2 is severe or extensive ectopy:\> 50%, 3 is moderate ectopy: 25-50%, 4 is mild ectopy: \<25% and 5 is no ectopy). |
| Vaginal health status measured by Bachmann Index. | 3,6 and 12 months | Evaluate vaginal health status from the start of treatment measured by Bachmann Index, it contains 5 domains that evaluate elasticity, type of secretion, pH, epithelial integrity and moisture, scoring each of them from 1 to 5, considering the maximum score as the best vaginal health status. |
| Satisfaction of papilocare gel use measured by likert scale. | 3 and 6 months | Evaluate the satisfaction of papilocare gel use by the patients after the start of treatment measured by likert scale, it is a single-item instrument that assesses the degree of satisfaction experienced by the patient with a graded response of 7 values ranging from 1 (satisfied) to 7 (not satisfied at all). |
| Therapeutic compliance | 3 and 6 months | Evaluate the therapeutic compliance from the start of treatment |
Countries
Spain
Outcome results
None listed